Krsnaa Diagnostics Ltd - 543328 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Report of Monitoring Agency under Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and under Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended December 31, 2023 issued by ICICI Bank Limited. Krsnaa Diagnostics Ltd - 543328 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement pertaining to the Unaudited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2023. Krsnaa Diagnostics Ltd - 543328 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Audio Recording of Earnings Call dated February 13, 2024. Q3FY24 Quarterly & 9MFY24 Result Announced for Krsnaa Diagnostics Ltd.
Healthcare Services company Krsnaa Diagnostics announced Q3FY24 & 9MFY24 results: Q3FY24 Financial Highlights: In Q3FY24, the core business generated a revenue of Rs 1,583 million, marking a significant 34% year-on-year growth from Rs 1,180 million in Q3FY23. Revenue from operations for the core business in Q3FY24 stood at Rs 1,583 million, compared to Rs 1,181 million in Q3FY23. Other income in Q3FY24 was Rs 41 million, slightly lower than the Rs 45 million reported in Q3FY23. Total income in Q3FY24 reached Rs 1,624 million, compared to Rs 1,226 million in Q3FY23. EBITDA for the core business in Q3FY24 was Rs 378 million, showing a substantial 27% increase from Rs 298 million in Q3FY23. The EBITDA margin for the core business was 24% in Q3FY24, slightly lower than the 25% reported in Q3FY23. EBIT for the core business in Q3FY24 amounted to Rs 202 million, similar to the Rs 200 million reported in Q3FY23. The EBIT margin for the core business was 13% in Q3FY24, lower than the 17% reported in Q3FY23. Profit after tax (PAT) for the core business in Q3FY24 was Rs 130 million, representing a 5% decrease from Rs 136 million in Q3FY23. The PAT margin for the core business was 8% in Q3FY24, lower than the 12% reported in Q3FY23. The reported diluted earnings per share (EPS) for the core business in Q3FY24 was Rs 3.97, compared to Rs 4.24 in Q3FY23. 9MFY24 Financial Highlights: Core business revenue amounted to Rs 4,533 million, reflecting a robust 28% year-on-year growth from Rs 3,532 million in 9MFY23. Revenue from operations totaled Rs 4,533 million, up from Rs 3,539 million in 9MFY23. Other income amounted to Rs 125 million, down from Rs 135 million in 9MFY23. Total income was Rs 4,658 million, up from Rs 3,674 million in 9MFY23. EBITDA stood at Rs 1,020 million, compared to Rs 891 million in 9MFY23. EBITDA margin was 23%, consistent with the margin in 9MFY23. EBIT totaled Rs 566 million, down from Rs 621 million in 9MFY23. EBIT margin was 12%, consistent with the margin in 9MFY23. PAT amounted to Rs 381 million, down from Rs 432 million in 9MFY23. PAT margin was 8%, down from 12% in 9MFY23. Over the nine months of FY24, the reported diluted EPS was Rs 11.71, down from Rs 13.42 in 9MFY23. Operational Highlights for Q3FY24: Krsnaa has been short-listed to provide 17 MRI and 17 CT scan services in Maharashtra. Krsnaa has been shortlisted to provide MRI services in 5 Districts in Madhya Pradesh. Bagged contract to provide HPLC test at 21 districts in Maharashtra. Krsnaa has operationalized the pathology project in Assam. Krsnaa expanded its presence by establishing 195 new centers across the nation. Commenting on the Business, Pallavi Bhatevara, Managing Director, said: "We are one of the leaders benefiting from the transformation in the diagnostic industry, with the government's focus on providing the best healthcare facilities to all. In the Interim budget, there has been a focus on increasing the number of medical colleges pan India and including ASHA workers and Anganwadi Workers and helpers in the Ayushman Bharat Scheme. These policy measures would bring more people under the fold of public healthcare. Krsnaa Diagnostics Limited continues to play a major role in providing high-quality and affordable diagnostic services. The provision of high-quality and affordable diagnostic services stands as a fundamental pillar within the healthcare industry. It is with great pleasure that I announce our successful execution of an agreement for the Assam Pathology tender, a significant opportunity that encompasses 10 Labs and 1,256 collection centers. This development significantly enhances our presence, covering all districts of Assam. At present, Krsnaa Diagnostics is well-positioned to deploy 54 CT Scan machines, and 24 MRI machines, establish 156 labs, and set up 2,768 collection centers, all under various contractual agreements. These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their proficiency in navigating the intricate bidding process, meeting all requirements, and ultimately securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, establishing a solid foundation for sustainable, long-term growth." Result PDF
Krsnaa Diagnostics Q3 net profit down 4.4% at Rs 13 crore
Krsnaa Diagnostics' Q3 revenue, however, was up 34 percent from the year-ago period at Rs 158.3 crore Krsnaa Diagnostics Ltd - 543328 - Intimation Of Proposed Formation Of A Wholly Owned Subsidiary Company.
Intimation of Proposed formation of a Wholly owned Subsidiary Company. Krsnaa Diagnostics Ltd - 543328 - Announcement under Regulation 30 (LODR)-Resignation of Managing Director
Intimation under Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Resignation of Ms. Pallavi Bhatevara from the position of Managing Director of the Company and she will continue contributing to the Company by working as an Executive Director on the Board of the Company. Krsnaa Diagnostics Ltd - 543328 - Announcement under Regulation 30 (LODR)-Investor Presentation
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Investor Presentation. Krsnaa Diagnostics Ltd - 543328 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release-Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023.